Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Biopharma Informatic

Neither a doctor nor a teaching hospital

Research payments

$691,824

343 payments

Through program year 2025, Biopharma Informatic is reported as receiving $691,824 in research payments, across 343 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $383,529 259
2024 Research $281,220 81
2023 Research $27,074 3

Breakdown

Who paid Research payments · program years 2023–2025
  1. Boehringer Ingelheim International GmbH $291,764 203 payments
  2. Janssen Research & Development, LLC $111,833 28 payments
  3. Biogen, Inc. $102,336 3 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $73,072 22 payments
  5. Amgen Inc. $61,870 7 payments
  6. Ascendis Pharma, Inc. $26,914 73 payments
  7. Insmed, Inc. $14,861 4 payments
  8. Novartis Pharmaceuticals Corporation $6,211 2 payments
  9. GlaxoSmithKline, LLC. $2,963 1 payment
Studies the money was for Research payments · program years 2023–2025
  1. A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis $121,217 59 payments
  2. A Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS) (CYPRESS) $102,336 3 payments
  3. A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis $88,730 75 payments
  4. A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) $72,371 17 payments
  5. BAY 948862, Clinical characteristics, treatment patterns and outcomes of patients treated with Finerenone in routine clinical practice A prospective non-interventional study. $60,768 13 payments
  6. BI 456906 in NAFLD $53,018 2 payments
  7. 70033093Acs3003 $39,462 11 payments
  8. EAP of Palopegteriparatide in Patients With Hypoparathyroidism $26,914 73 payments
  9. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity $25,856 2 payments
  10. Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) $20,799 66 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record